Prolium Bioscience is a clinical-stage biotechnology company headquartered in New York City. Its lead program, PRO-203, is a bispecific CD20xCD3 antibody intended to treat systemic sclerosis and other severe autoimmune disorders by simultaneously engaging B and T cells. The therapeutic approach aims to deliver targeted immunomodulation with improved efficacy and safety over existing treatments. The company is led by CEO Scott Requadt and has assembled a team experienced in autoimmune drug development. With fresh Series A capital, Prolium plans to accelerate research and development while expanding operational capabilities to support clinical advancement. As an early-stage biotech, it has not yet reported commercial revenue, focusing resources on progressing PRO-203 through clinical trials.

Total raised

$50M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2026